Masi, Mirco; Poppi, Laura; Previtali, Viola; Nelson, Shannon R; Wynne, Kieran; Varignani, Giulia; Falchi, Federico; Veronesi, Marina; Albanesi, Ennio; Tedesco, Daniele; De Franco, Francesca; Ciamarone, Andrea; Myers, Samuel H; Ortega, Jose Antonio; Bagnolini, Greta; Ferrandi, Giovanni; Farabegoli, Fulvia; Tirelli, Nicola; Di Stefano, Giuseppina; Oliviero, Giorgio; Walsh, Naomi; Roberti, Marinella; Girotto, Stefania; Cavalli, Andrea, Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity, «CELL DEATH DISCOVERY», 2025, 11, pp. 1 - 23 [Scientific article]
Bagnolini G., Poppi L., Previtali V., Ferrandi G., Rinaldi F., Girotto S., Hirsch A.K.H., Roberti M., Cavalli A., A journey through targeting BRCA2-RAD51 protein-protein interaction to establish synthetic lethality as paradigm for anticancer drug discovery, in: National Congress of the Italian Chemistry Society 2024, 2024, pp. 1 - 999 (atti di: SCI 2024 Chemistry ELEMENTS OF FUTURE, Milano, 26/08/2024) [Contribution to conference proceedings]
Ferrandi, Giovanni; Poppi, Laura; Bagnolini, Greta; Previtali, Viola; Roberti, Marinella; Cavalli, Andrea, Design and synthesis of RAD51-BRCA2 disruptors to inhibit homologous recombination and achieve synthetic lethality in pancreatic cancer cells, in: XXVIII EFMC International Symposium on Medicinal Chemistry, 2024(atti di: XXVIII EFMC International Symposium on Medicinal Chemistry, Roma, 1st September 2024) [Poster]
Ferrandi, Giovanni; Poppi, Laura; Bagnolini, Greta; Falchi, Federico; Previtali, Viola; Girotto, Stefania; Roberti, Marinella; Cavalli, Andrea, Design and synthesis of RAD51-BRCA2 protein-protein interaction disruptors
to trigger synthetic lethality with Olaparib in pancreatic cancer cells, in: National Congress of the Italian Chemistry Society 2024, 2024(atti di: SCI 2024 Chemistry ELEMENTS OF FUTURE, Milano, 26th August 2024) [Poster]
Previtali, Viola; Bagnolini, Greta; Ciamarone, Andrea; Ferrandi, Giovanni; Rinaldi, Francesco; Myers, Samuel Harry; Roberti, Marinella; Cavalli, Andrea, New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives, «JOURNAL OF MEDICINAL CHEMISTRY», 2024, 1, pp. 11488 - 11521 [Scientific article]Open Access
Myers, S. H.; Poppi, L.; Rinaldi, F.; Veronesi, M.; Ciamarone, A.; Previtali, V.; Bagnolini, G.; Schipani, F.; Ortega Martínez, J. A.; Girotto, S.; Di Stefano, G.; Farabegoli, F.; Walsh, N.; De Franco, F.; Roberti, M.; Cavalli, A., An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer, «EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY», 2023, 265, Article number: 116114 , pp. 1 - 20 [Scientific article]Open Access
Ferrandi, Giovanni; Bagnolini, Greta; Roberti, Marinella; Cavalli, Andrea, Design and synthesis of RAD51-BRCA disruptors to inhibit homologous recombination and achieve synthetic lethality in cancer cells, in: 42nd edition of European School of Medicinal Chemistry, ESMEC, 2023(atti di: European School of Medicinal Chemistry, ESMEC, Urbino, 2nd July 2023) [Poster]
Bagnolini, G.; Falchi, F.; Sdei, F.; Roberti, M.; Sosic, A.; Sissi, C.; Bolognesi, M. L., Triggering RNA degradation with small molecules: development of RIBOnuclease TArgeting Chimeras (RIBOTACs), in: Book of abstract, 2023(atti di: XXVIII National Meeting on Medicinal Chemistry (NMMC28), Chieti, 17-20 September 2023) [Poster]
Bagnolini, G.; Balboni, B.; Schipani, F.; Gioia, D.; Veronesi, M.; De Franco, F.; Kaya, C.; Jumde, R. P.; Ortega, J. A.; Girotto, S.; Hirsch, A. K. H.; Roberti, M.; Cavalli, A., Identification of RAD51-BRCA2 Inhibitors Using N-Acylhydrazone-Based Dynamic Combinatorial Chemistry, «ACS MEDICINAL CHEMISTRY LETTERS», 2022, 13, pp. 1262 - 1269 [Scientific article]Open Access
Previtali V., Myers S. H., Bagnolini G., Poppi L., Rinaldi F., Schipani F., Ortega J. A., De Franco F., Pellicciari R., Girotto S., Oliviero G., Walsh N., Valenti G., Tirelli N., Di Stefano G., Roberti M., Cavalli A., Insights into the activity of ARN24089, a new RAD51-BRCA2 disruptor that inhibits homologous recombination and achieves synthetic lethality in pancreatic cancer, in: ACS Spring 2022, 2022, pp. 1 - 1 (atti di: ACS Spring 2022, San Diego Convention Center, Room 16A, 20/03/2023) [Abstract]
Mazzei L.; Contaldo U.; Musiani F.; Cianci M.; Bagnolini G.; Roberti M.; Ciurli S., Inhibition of Urease, a Ni-Enzyme: The Reactivity of a Key Thiol With Mono- and Di-Substituted Catechols Elucidated by Kinetic, Structural, and Theoretical Studies, «ANGEWANDTE CHEMIE. INTERNATIONAL EDITION», 2021, 60, pp. 6029 - 6035 [Scientific article]Open Access
Bagnolini G.; Milano D.; Manerba M.; Schipani F.; Ortega J.A.; Gioia D.; Falchi F.; Balboni A.; Farabegoli F.; De Franco F.; Robertson J.; Pellicciari R.; Pallavicini I.; Peri S.; Minucci S.; Girotto S.; Di Stefano G.; Roberti M.; Cavalli A., Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib, «JOURNAL OF MEDICINAL CHEMISTRY», 2020, 63, pp. 2588 - 2619 [Scientific article]Open Access
Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, Domenico Milano, Elisa Giacomini, Federico Falchi, Andrea Balboni, Marcella Manerba, Fulvia Farabegoli, Francesca De Franco, Janet Robertson, Saverio Minucci, Isabella Pallavicini, Giuseppina Di Stefano, Stefania Girotto, Roberto Pellicciari, and Andrea Cavalli, Rad51/Brca2 Disruptors Inhibit Homologous Recombination and Synergize with
Olaparib in Pancreatic Cancer Cells, «EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY», 2019, 165, pp. 80 - 92 [Scientific article]
